Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Prednisolone for COPD exacerbations: time for a rethink.

Ramakrishnan S., (2023), ERJ open research, 9, 464 - 2023

Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST)

Howell I. et al, (2023), JMIR Research Protocols, 12, e46741 - e46741

Patients’ acceptance of outcome and experience measurements during hospitalisation for COPD exacerbations: a cicero CRC - ELF online patient survey

Gyselinck I. et al, (2023), ERJ Open Research, 00148 - 2023

Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST) (Preprint)

Howell I. et al, (2023)

Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19

Cass S. et al, (2023)

Chronic obstructive pulmonary disease: 10 years of precision-guided success

Ramakrishnan S., (2023), The Lancet Respiratory Medicine, 11, 227 - 228

Maintenance Pulmonary Rehabilitation

Ramakrishnan S., (2022), Chest, 162, 1227 - 1228

Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis

Baker JR. et al, (2022), The Lancet Respiratory Medicine, 10, 545 - 556

Ethnicity-based differences in asthma diagnostic thresholds

Mwasuku C. et al, (2022), The Journal of Allergy and Clinical Immunology: In Practice, 10, 1124 - 1124

European Respiratory Society International Congress 2021: highlights from best-abstract awardees

Ramakrishnan S. et al, (2022), Breathe, 18, 210176 - 210176

COPD Exacerbations: Do All Roads Lead to Rome?

Ramakrishnan S. et al, (2022), American journal of respiratory and critical care medicine

Heterogeneity of IPF exacerbations.

Ramakrishnan S. and Bafadhel M., (2022), Lancet Respir Med, 10

POINT OF CARE BLOOD EOSINOPHIL GUIDED ORAL PREDNISOLONE FOR COPD EXACERBATIONS: A MULTICENTRE DOUBLE BLIND RANDOMISED CONTROLLED TRIAL (THE STARR2 TRIAL)

Ramakrishnan S. et al, (2022), THORAX, 77, A3 - A4

Point of care blood eosinophil guided oral prednisolone for COPD exacerbations: a multi-centre double blind randomised controlled trial (The STARR2 trial)

Ramakrishnan S. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60

PROM and PREM preferences in COPD-patients

Gyselinck I. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60

TO WHAT EXTENT DOES THE PROTOTYPE ORACLE SCALE PREDICT TREATMENT BENEFITS? PREDICTED VERSUS OBSERVED IMPACT OF ANTI-INFLAMMATORY TREATMENTS

Couillard S. et al, (2021), THORAX, 76, A175 - A176

Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19

Baker JR. et al, (2021)

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial

Ramakrishnan S. et al, (2021), Respiratory infections and bronchiectasis

Patient perspective of participation in COVID-19 clinical trials

Krassowska K. et al, (2021), Nurses

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Yu L-M. et al, (2021), The Lancet, 398, 843 - 855

Load More

Include forthcoming?